Aptose Biosciences Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 9 - Warrants

Note 9 - Warrants

3 Months Ended

Mar. 31, 2026

Warrants and Rights Note Disclosure [Abstract]

A summary of warrant activity during the three months ended March 31, 2026 is as follows:


	Common shares issuable upon exercise			Weighted average exercise price		Weighted average remaining contractual life (years)
Outstanding as of December 31, 2025		1,267,585		$	22.40		3.3
Forfeited/expired		(128,500	)		34.50
Outstanding as of March 31, 2026		1,139,085		$	21.04		3.4
Exercisable as of March 31, 2026		1,139,085		$	21.04		3.4

The following table shows the number of outstanding warrants by exercise price and date of expiration as of March 31, 2026:


Shares Issuable Upon Exercise		Exercise Price			Expiration Date

	18,084		$	64.13	January 30, 2028
	188,174		$	51.30	January 30, 2029
	77,972		$	51.30	January 31, 2029
	6,423		$	43.13	June 3, 2029
	128,500		$	34.50	September 5, 2029
	666,599		$	6.00	November 25, 2029
	53,333		$	8.25	November 25, 2029
	1,139,085

Upon full exercise of all the warrants exercisable as of March 31, 2026, the Company would issue an additional 1,139,085 of its Common Shares, which could have a dilutive effect on existing shareholders.